Immunity to and frequency of reinfection with respiratory syncytial virus.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Journal of Infectious Diseases

• Publication date

  1991-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/INFDIS/163.4.693PMID 2010624
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus.

  1990cited by this paper
• Respiratory syncytial virus-specific antibody responses in immunoglobulin A and E isotypes to the F and G proteins and to intact virus after natural infection

  1989cited by this paper
• Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses

  1988cited by this paper
• Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity

  1988cited by this paper
• Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus.

  1988cited by this paper
• Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection.

  1987cited by this paper
• Immunological differences between the envelope glycoproteins of two strains of human respiratory syncytial virus.

  1987cited by this paper
• Subgroup characteristics of respiratory syncytial virus strains recovered from children with two consecutive infections

  1987cited by this paper
• Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity

  1987cited by this paper
• Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus.

  1987cited by this paper
• Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity.

  1986cited by this paper
• Concurrent circulation of antigenically distinct strains of respiratory syncytial virus during community outbreaks.

  1986cited by this paper
• Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein.

  1986cited by this paper
• Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection

  1986cited by this paper
• Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus

  1986cited by this paper
• Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection

  1986cited by this paper
• Risk of primary infection and reinfection with respiratory syncytial virus.

  1986cited by this paper
• Serum immunoglobulin G antibody subclass responses to respiratory syncytial virus F and G glycoproteins after primary infection

  1986cited by this paper
• Analysis of the respiratory syncytial virus fusion protein using monoclonal and polyclonal antibodies.

  1986cited by this paper
• Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine

  1986cited by this paper
• Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge

  1986cited by this paper
• Antigenic variation between human respiratory syncytial virus isolates.

  1986cited by this paper
• Purification and characterization of the respiratory syncytial virus fusion protein.

  1985cited by this paper
• Two distinct subtypes of human respiratory syncytial virus.

  1985cited by this paper
• Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay

  1985cited by this paper
• Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies.

  1985influential reference
• Purification and characterization of GP90, one of the envelope glycoproteins of respiratory syncytial virus.

  1984cited by this paper
• Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies

  1984cited by this paper
• Monoclonal antibodies protect against respiratory syncytial virus infection in mice.

  1984cited by this paper
• Antibodies to respiratory syncytial virus polypeptides and their significance in human infection.

  1983influential reference
• Cellular and Humoral Immunity in Recurrent Respiratory Syncytial Virus Infections

  1983cited by this paper
• Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein

  1983cited by this paper
• Maternal antibody and respiratory syncytial virus infection in infancy

  1981cited by this paper
• Monoclonal antibodies to respiratory syncytial virus: detection of virus neutralization and other antigen-antibody systems using infected human and murine cells.

  1981cited by this paper
• Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level.

  1981cited by this paper
• Secretory antibody response to respiratory syncytial virus infection.

  1981cited by this paper
• Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children.

  1979cited by this paper
• The immunologic response to infection with respiratory syncytial virus in infants.

  1978cited by this paper
• Respiratory syncytial virus infections within families.

  1976cited by this paper
• Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex.

  1973cited by this paper
• Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness.

  1971cited by this paper
• Influence of immunological factors in respiratory syncytial virus disease.

  1970cited by this paper

• Serological evidence of substantial respiratory syncytial virus infection burden among older adults residing in Swedish long-term care facilities

  2026cites this paper
• The soluble G protein of respiratory syncytial virus promotes viral dissemination via TLR2-mediated NLRP3 priming and pyroptosis

  2026cites this paper
• A Phase IIa randomized clinical trial of a respiratory syncytial virus and human metapneumovirus combination protein-based virus-like particle vaccine in adults 60-85 years of age.

  2026cites this paper
• Respiratory Syncytial Virus in Hematopoietic Cell Transplant Recipients: Clinical and Humoral Risk Factors for Infection

  2026cites this paper
• Mucosal immunization with an adenoviral vector expressing a prefusogenic F protein protects the upper and lower respiratory tracts of cotton rats against live respiratory syncytial virus challenge

  2026cites this paper
• The burden, pathogenesis, clinical outcomes, and treatment of common respiratory virus infections during pregnancy

  2025cites this paper
• Epidemiological and phylogenetic characterization of human respiratory syncytial virus associated with severe acute respiratory infections in paediatric patients from 2016 to 2023 in Hangzhou, China

  2025cites this paper
• Improved mRNA-based RSV vaccine with PreF forming enveloped virus-like particles

  2025cites this paper
• Prophylaxis of RSV Infection in Infants

  2025cites this paper
• Robust and Long-Lasting Immunity and Protection in Mice Induced by Lipopolyplex-Delivered mRNA Vaccines Expressing the Prefusion Protein of Respiratory Syncytial Virus

  2025cites this paper
• Risk analysis for outpatient experimental infection as a pathway for affordable RSV vaccine development

  2025cites this paper
• RSV: an update on prevention and management

  2025cites this paper
• Economic evaluations of RSV preventive strategies: a systematic review of cost-effectiveness and modeling approaches

  2025cites this paper
• Safety, Tolerability, and Immunogenicity of Revaccination with mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years.

  2025cites this paper
• Molecular Mechanisms of Respiratory Syncytial Virus Pathogenesis.

  2025cites this paper
• Seroprevalence of RSV IgG Antibodies Across Age Groups in Poland After the COVID-19 Pandemic: Data from the 2023/2024 Epidemic Season

  2025cites this paper
• Exact results for the stochastic SIS epidemic model in densely populated environments

  2025cites this paper
• Seroprevalence of RSV Antibodies in a Contemporary (2022 - 2023) Cohort of Adults.

  2025cites this paper
• Exploring quercetin based nano formulation in combating human Metapneumovirus infections.

  2025cites this paper
• Current status of developments in the field of respiratory syncytial virus vaccines

  2025cites this paper
• Determinants of respiratory syncytial virus and human metapneumovirus transmission

  2025cites this paper
• Update on vaccines against respiratory syncytial virus (RSV): A narrative review.

  2025cites this paper
• A Randomized Phase 1 Clinical Trial of a Respiratory Syncytial Virus and Human Metapneumovirus Combination Protein-Based Virus-like Particle Vaccine in Adults 60–75 Years of Age

  2025cites this paper
• Immune and Virological Factors Influencing Human Respiratory Syncytial Virus Circulation and Increased Prevalence During and After the COVID-19 Pandemic

  2025cites this paper
• Decreased Fc fucosylation aligns with enhanced RSV-specific antibody functionality in adults compared to young children

  2025cites this paper
• Host immune response to respiratory syncytial virus infection and its contribution to protection and susceptibility in adults: a systematic literature review

  2025cites this paper
• Review of impaired immune parameters in RSV infections in the elderly.

  2025cites this paper
• Prevalence and impact of SARS-CoV-2, influenza, respiratory syncytial virus (RSV) infection and respiratory illness on UK healthcare workers during winter 2023/24 (September 2023 to March 2024): SIREN cohort study

  2025cites this paper
• The Role of Ribavirin for Treatment of Respiratory Syncytial Virus in Immunocompromised Patients

  2025cites this paper
• Rationalizing recommendations for influenza and COVID-19 vaccines.

  2025cites this paper
• RSV F evolution escapes some monoclonal antibodies but does not strongly erode neutralization by human polyclonal sera

  2025cites this paper
• The Differential Early Responses of Human Leukocytes to Influenza Virus and Respiratory Syncytial Virus

  2025cites this paper
• Seroprevalence of RSV Antibodies in a Contemporary Cohort of Adults in Southeast Minnesota

  2025influential citation
• Assessment of specific IgA and Interferon gamma levels in serum of children with respiratory syncytial virus infection

  2025cites this paper
• Respiratory Syncytial Virus Humoral Antibody Responses in Older Adults After Vaccination or Infection

  2025cites this paper
• RSV F evolution escapes some monoclonal antibodies but does not strongly erode neutralization by human polyclonal sera

  2025cites this paper
• Strength and Durability of Respiratory Syncytial Virus Prefusion F Immunoglobulin G Following Infection and Exposure in a Household Cohort, 2014–2022

  2025cites this paper
• Surfactant Protein-A (SP-A) and its Immunomodulatory Roles in Infant Respiratory Syncytial Virus (RSV) Infection - a potential for therapeutic intervention?

  2024cites this paper
• Characterizing the interactions between influenza and respiratory syncytial viruses and their implications for epidemic control

  2024cites this paper
• Acceptance and safety of the RSV-preventive treatment of newborns with nirsevimab in the maternity department: a prospective longitudinal cohort study in France

  2024cites this paper
• Modelling the epidemiological impact of maternal respiratory syncytial virus (RSV) vaccination in Australia.

  2024cites this paper
• Biology of human respiratory syncytial virus: Current perspectives in immune response and mechanisms against the virus

  2024cites this paper
• Evaluation of adenoviral vector Ad19a encoding RSV-F as novel vaccine against respiratory syncytial virus

  2024cites this paper
• Long-term efficacy and immunogenicity of Ad26.RSV.preF-RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study.

  2024cites this paper
• Virus neutralization assays for human respiratory syncytial virus using airway organoids

  2024cites this paper
• Eco-evolutionary dynamics of pathogen immune-escape: deriving a population-level phylodynamic curve

  2024cites this paper
• Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions

  2024cites this paper
• Development of innate and adaptive immunity to RSV in young children.

  2024cites this paper
• Herd immunity to endemic diseases: Historical concepts and implications for public health policy.

  2024cites this paper
• Viral infections causing asthma exacerbations in the age of biologics and the COVID-19 pandemic

  2024cites this paper
• Vaccines against respiratory syncytial virus

  2024cites this paper
• RSV in transplant and immunocompromised patients.

  2024cites this paper
• No association between disease severity and respiratory syncytial virus subtypes RSV-A and RSV-B in hospitalized young children in Norway

  2024cites this paper
• Respiratory syncytial virus incidence and typing in the last six seasons in the north of Spain (Asturias). Genetic characterization during the SARS‐CoV‐2 pandemic

  2024cites this paper
• A Mixture of T-Cell Epitope Peptides Derived from Human Respiratory Syncytial Virus F Protein Conferred Protection in DR1-TCR Tg Mice

  2024cites this paper
• Modelling respiratory syncytial virus age-specific risk of hospitalisation in term and preterm infants

  2024cites this paper
• Prevention and Potential Treatment Strategies for Respiratory Syncytial Virus

  2024cites this paper
• The Respiratory Syncytial Virus (RSV) G Protein Enhances the Immune Responses to the RSV F Protein in an Enveloped Virus-Like Particle Vaccine Candidate

  2023cites this paper
• The Efficiency of p27 Cleavage during In Vitro Respiratory Syncytial Virus (RSV) Infection Is Cell Line and RSV Subtype Dependent

  2023cites this paper
• Modeling the effects of farming practices on bovine respiratory disease in a multi-batch cattle fattening farm.

  2023cites this paper
• The road to approved vaccines for respiratory syncytial virus

  2023cites this paper
• Circulation of Respiratory Viruses in the City: Towards an Agent-Based Ecosystem model

  2023cites this paper
• The age profile of respiratory syncytial virus burden in preschool children of low- and middle-income countries: A semi-parametric, meta-regression approach

  2023cites this paper
• The continuing need for therapeutic agents for respiratory syncytial virus infection

  2023cites this paper
• Difference in respiratory syncytial virus-specific Fc-mediated antibody effector functions between children and adults

  2023cites this paper
• Application of Baculovirus Expression Vector System (BEVS) in Vaccine Development

  2023cites this paper
• Preventative therapies for respiratory Syncytial virus (RSV) in children: Where are we now?

  2023cites this paper
• Advances in clinical development for vaccines and therapeutics against respiratory virus infections

  2023cites this paper
• Development of Respiratory Syncytial Virus Vaccine Candidates for the Elderly

  2023cites this paper
• Immunization with a mucosal, post-fusion F/G protein-based polyanhydride nanovaccine protects neonatal calves against BRSV infection

  2023cites this paper
• Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus

  2023cites this paper
• Common cold

  2023cites this paper
• Human T cells efficiently control RSV infection

  2023cites this paper
• Respiratory Syncytial Virus-Specific Antibodies and Atopic Diseases in Children: A 10-Year Follow-Up

  2023cites this paper
• Respiratory Syncytial Virus-An Update for Prenatal and Primary Health Providers.

  2023cites this paper
• Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial

  2023cites this paper
• RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models

  2023cites this paper
• Development of a Kinetic ELISA and Reactive B Cell Frequency Assay to Detect Respiratory Syncytial Virus Pre-Fusion F Protein-Specific Immune Responses in Infants.

  2023cites this paper
• Immunogenicity and protective efficacy of an RSV G S177Q central conserved domain nanoparticle vaccine

  2023cites this paper
• Establishment and validation of a High-throughput Micro-Neutralization assay for Respiratory Syncytial Virus (subtypes A and B)

  2023cites this paper
• Understanding the SARS-CoV-2 Virus Neutralizing Antibody Response: Lessons to Be Learned from HIV and Respiratory Syncytial Virus

  2023cites this paper
• Nirsevimab: review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants.

  2023cites this paper
• The Quest for a Respiratory Syncytial Virus Vaccine for Older Adults: Thinking beyond the F Protein

  2023cites this paper
• Expert consensus on the diagnosis, treatment, and prevention of respiratory syncytial virus infections in children

  2023cites this paper
• Natural immune boosting can cause synchrony in susceptibility and outbreaks of respiratory infections with rapidly waning immunity

  2023cites this paper
• Outpatient respiratory syncytial virus infections and novel preventive interventions

  2023cites this paper
• Prevention and Treatment Strategies for Respiratory Syncytial Virus (RSV)

  2023cites this paper
• Respiratory syncytial virus reinfections among infants and young children in the United States, 2011–2019

  2023cites this paper
• Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine

  2023cites this paper
• Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge Trial of MVA-BN-RSV Vaccine

  2023cites this paper
• Vaccination for Respiratory Syncytial Virus: A Narrative Review and Primer for Clinicians

  2023cites this paper
• Emergence of a reversed backward bifurcation, reversed hysteresis effect, and backward bifurcation phenomenon in a COVID‐19 mathematical model

  2023influential citation
• Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7–8, 2022

  2023cites this paper
• Value profile for respiratory syncytial virus vaccines and monoclonal antibodies.

  2023cites this paper
• Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adults.

  2023cites this paper
• Toward a global virus genomic surveillance network

  2023cites this paper
• Respiratory Syncytial Virus Infections in Neonates: A Persisting Problem

  2023cites this paper
• Longitudinal study of the immune response and memory following natural bovine respiratory syncytial virus infections in cattle of different age

  2022cites this paper
• The Respiratory Syncytial Virus G Protein Enhances the Immune Responses to the RSV F Protein in an Enveloped Virus-like Particle Vaccine Candidate

  2022cites this paper
• Emergence of: a reversed backward bifurcation , reversed hysteresis effect and backward bifurcation phenomenon in a COVID-19 mathematical model (preprint)

  2022influential citation